


PRODUCT INFORMATION



Branebrutinib

Item No. 33462

CAS Registry No.: 1912445-55-6
Formal Name: 5-fluoro-2,3-dimethyl-4-[(3S)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]-1H-indole-7-carboxamide
Synonym: BMS-986195
MF: C₂₀H₂₃FN₄O₂
FW: 370.4
Purity: ≥98%
UV/Vis.: λ_{max}: 242, 329 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Branebrutinib is supplied as a crystalline solid. A stock solution may be made by dissolving the branebrutinib in the solvent of choice, which should be purged with an inert gas. Branebrutinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of branebrutinib in ethanol is approximately 1 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Branebrutinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, branebrutinib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Branebrutinib has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Branebrutinib is a covalent inhibitor of Bruton's tyrosine kinase (BTK; IC₅₀ = 0.1 nM).¹ It is greater than 5,000-fold selective for BTK over a panel of 240 kinases but does inhibit the additional Tec family kinases Tec, BMX, and TMX (IC₅₀s = 0.9, 1.5, and 5 nM, respectively). Branebrutinib inhibits calcium flux in Ramos B cells induced by B cell receptor (BCR) stimulation (IC₅₀ = 7.2 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC₅₀s = 0.04 and 0.3 nM, respectively). It inhibits TNF-α production in human peripheral blood mononuclear cells (PMBCs) induced by Fcγ receptor stimulation (IC₅₀ = 0.3 nM). Branebrutinib (0.5 mg/kg) is completely protective against bone destruction in a mouse model of collagen-induced arthritis. It also reduces proteinuria and glomerular IgG immune complex deposition and increases survival in an NZB/W lupus-prone mouse model.

Reference

1. Watterson, S.H., Liu, Q., Bertrand, M.B., *et al.* Discovery of branebrutinib (BMS-986195): A strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton's tyrosine kinase (BTK). *J. Med. Chem.* **62**(7), 3228-3250 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM